Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $167.0K | $204.0K | $227.0K | $262.0K | $280.0K | $311.0K | $484.0K | $803.0K |
| Gross profit | −$167.0K | −$204.0K | −$227.0K | −$262.0K | −$280.0K | −$311.0K | −$484.0K | −$803.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $5.1M | $7.0M | $9.5M | $9.1M | $9.9M | $19.7M | $16.0M | $10.4M |
| Operating income | −$7.9M | −$9.9M | −$13.9M | −$15.7M | −$13.9M | −$26.8M | −$23.3M | −$14.3M |
| EBITDA | −$7.8M | −$9.8M | −$13.6M | −$15.4M | −$13.7M | −$26.5M | −$22.8M | −$13.8M |
| Net income | −$8.0M | −$11.4M | −$14.0M | −$18.9M | −$25.5M | −$31.2M | −$24.2M | −$17.0M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -512.93 | -496.65 | -418.32 | -448.88 | -170.19 | -105.38 | -55.40 | -12.54 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $34M | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds BPTS.
No tracked institution reports a position in BPTS as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-04-23 | 1-for-40reverse |
| 2023-03-30 | 1-for-10reverse |
No one on the platform has traded BPTS yet.
| $2M |
| — |
| IDRAIdera Pharmaceuticals, Inc. | $0.42 | -23.04% | $0 | — |
| NOVNNovan, Inc. | $0.09 | -24.84% | $3M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
$BPTS Anyone know what is going on with this stock? The symbol now being BPTSY. I tried buying more shares at this low price, but broker blocked me.
View on StockTwits ↗$BPTS anyone have info on this? Could it be why stock went up oddly today? https://www.biophytis.com/en/biophytis-announces-the-temporary-suspension-of-the-trading-of-its-shares/ I feel like I’m on a desert filled with crickets when I check this stock daily. Hoping to not be all alone out here soon 😂
View on StockTwits ↗ATER remains wildly undervalued. $14–$21 DCF range TEMU deal = international scale Buyback in play, no dilution Chart is tightening. 500%+ potential in sight. $GLTO $BPTS $MDVL $GTBP $TRVN …
View on StockTwits ↗With the J-Code effective tomorrow I see $CTOR going for $2.00 this week. Could run just like $ALP and I'm in from last Monday so I can still add up to $1.00 tomorrow. $BPTS has potential when the dust settles from the private placement. Curious to see. Absolutely love the $PLRZ chart. 4M float, cash, and the books are clean enough for something magical to happen.
View on StockTwits ↗$BPTS Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia https://www.stocktitan.net/news/BPTS/biophytis-deploys-its-partnership-strategy-and-signs-two-contracts-qbza06b9fcsm.html
View on StockTwits ↗$BPTS Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity https://www.stocktitan.net/news/BPTS/biophytis-obtains-ind-approval-from-the-fda-to-start-its-phase-2-oba-iqssxto2z0d9.html
View on StockTwits ↗$BPTS Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris https://www.stocktitan.net/news/BPTS/biophytis-presented-its-phase-2-3-cova-study-results-in-severe-forms-i7dc26e4tsxg.html
View on StockTwits ↗$BPTS Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million https://www.stocktitan.net/news/BPTS/biophytis-grants-blanver-exclusive-rights-to-bio101-in-latin-america-nuazur6x0zom.html
View on StockTwits ↗$BPTS Biophytis Extends Its Contract With Atlas to Secure Financing for Its Business Activities https://www.stocktitan.net/news/BPTS/biophytis-extends-its-contract-with-atlas-to-secure-financing-for-t0u1zsgoiojc.html
View on StockTwits ↗$BPTS Biophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by its Service Provider Seqens https://www.stocktitan.net/news/BPTS/biophytis-announces-the-successful-industrial-transfer-of-bio101-20-sm0c5xfa050b.html
View on StockTwits ↗$BPTS Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity https://www.stocktitan.net/news/BPTS/biophytis-announces-the-design-of-its-phase-2-oba-clinical-study-in-9rclxhz8bt93.html
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.